Pressroom: Media Coverage

Showing 221 - 240 of 727 news items


NY Cancer Research Gets $90 Million

Immunologist Jedd Wolchok commented on a $90 million gift from Ludwig Cancer Research to support Memorial Sloan Kettering’s immunology research.

January 6, 2014
Cycle for Survival Raises Money for Cancer Research

Cycle for Survival, a national indoor team cycling event, raises money for research on rare cancers at Memorial Sloan Kettering.

January 3, 2014


India's Efforts to Aid Poor Worry Drug Makers

Epidemiologist Peter Bach commented on efforts to make drugs affordable to the world’s poorest people.

December 30, 2013
Millions at High Risk for Lung Cancer Should be Screened Yearly, Panel Says

Epidemiologist Peter Bach commented on recommendations from the U.S. Preventive Services Task Force for yearly screening of healthy adults between the ages of 55 and 80 at high risk for lung cancer.

December 30, 2013
Childhood Cancer's New Conundrum

Primary care physician Kevin Oeffinger and behavioral psychologist Tim Ahles commented on new research that suggests that survivors of childhood cancer are facing a new health challenge: premature aging.

December 27, 2013
Johanna Joyce, Cancer Warrior

Cancer biologist Johanna Joyce was profiled and discussed how she is challenging scientists to rethink the fight against cancer.

December 23, 2013
After Brief Halt, FDA Allows Sales of Drug for Cancer to Resume

Medical oncologist Michael Mauro commented on an FDA decision to resume sales of a leukemia drug that has been keeping patients alive but also comes with serious side effects.

December 21, 2013
Cancer Immunotherapy

Immunotherapy researchers Jedd Wolchok, Michel Sadelain, and Renier Brentjens played a leading role in pioneering the 2013 Science “Breakthrough of the Year”.

December 20, 2013
Adoptive Cell Therapy: Honing That Killer Instinct

Cell researcher Michel Sadelain spoke about adoptive cell transfer therapy, which genetically alters a patient’s immune cells to train them to attack cancer.

December 18, 2013
Drug Development: Releasing the Brakes

Immunologist Jedd Wolchok commented on new therapies called immune checkpoint blockades that free immune cells to attack cancer.

December 18, 2013
Hormone Used for Doping Is Made from Scratch

Research led by chemist Samuel Danishefsky has synthesized for the first time erythropoietin, the hormone that controls the production of red blood cells.

December 12, 2013
The Best and Worst Health Trends of 2013

Gynecologic surgeon Carol Brown discussed the benefits of the HPV vaccine.

December 11, 2013
Cancer Progress Threatened by Budget Cuts in Congress, Group Says

Medical oncologist Clifford Hudis stressed the need for more research funding to continue making progress in the fight against cancer.

December 10, 2013
Killing Cancer like the Common Cold

Physician-scientist Renier Brentjens commented on promising results of three separate studies of immunotherapies for leukemia.

December 9, 2013
Hopes Raised for Simplification of Cancer Research

Cancer biologist Joan Massagué who was recently named Director of the Sloan-Kettering Institute answered questions about the areas of cancer research that excite him.

December 9, 2013
Real Estate And Media Mogul Mort Zuckerman Continues To Spread His Influence Across New York And The World

Memorial Sloan-Kettering board member Mortimer Zuckerman was interviewed about his philanthropy, including his generous gift to Memorial Sloan-Kettering to construct the Mortimer B. Zuckerman Research Center.

December 9, 2013
Health Problems Common in Survivors of Pediatric Cancer

Internist Emily Tonorezos discussed some of the health issues survivors of pediatric cancer face.

December 8, 2013
Cancer Survivors Celebrate Their Cancerversary

Memorial Sloan-Kettering patient Bruce Feiler reflected on the five year anniversary of his cancer diagnosis. His surgeon John Healey was quoted.

December 7, 2013
Cancer Centers, Longtime Rivals, Launch Company to Develop New Drug

Memorial Sloan-Kettering has partnered with the Fred Hutchinson Cancer Research Center and the Seattle Children’s Research Institute to form a biotechnology company to speed the development of novel immunotherapies for cancer. Cell researchers Michel Sadelain, Isabelle Rivière, and Renier Brentjens are co-founders.

December 4, 2013
Dr. van den Brink on Adding Ibrutinib to R-CHOP in NHL

Hematologic Oncology Division Head Marcel van den Brink discusses a trial that analyzes the addition of ibrutinib to R-CHOP in patients with non-Hodgkin lymphoma. The trial will be presented at the 2013 American Society of Hematology Annual Meeting and Exposition.

December 4, 2013